MAP-2A Inhibitors
MAP-2A inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of MAP-2A (Microtubule-Associated Protein 2A), which is a member of the MAP family involved in the stabilization and regulation of microtubules in neurons. MAP-2A plays a critical role in maintaining the structural integrity of the neuronal cytoskeleton by binding to microtubules and promoting their assembly and stabilization. This protein is essential for the proper development and maintenance of dendritic structures in neurons, supporting cell shape, intracellular transport, and signaling processes. Inhibiting MAP-2A allows researchers to study the effects of disrupted microtubule dynamics on neuronal morphology, transport mechanisms, and overall cellular function.
The mechanism of MAP-2A inhibitors typically involves blocking the protein's ability to bind to microtubules, thereby preventing the stabilization and assembly of the microtubule network. These inhibitors may interact with critical binding domains on MAP-2A, such as its microtubule-binding regions, disrupting its interaction with tubulin. Structurally, MAP-2A inhibitors are designed to interfere with these binding interactions or induce conformational changes in the protein, reducing its affinity for microtubules. By studying MAP-2A inhibitors, researchers gain insights into the regulation of cytoskeletal dynamics in neurons and the broader impact of microtubule disruption on cellular processes such as intracellular trafficking, cell signaling, and neuronal plasticity. These inhibitors are valuable tools for exploring the specific role of MAP-2A in maintaining neuronal architecture and for understanding how changes in microtubule-associated proteins affect the broader cytoskeletal network.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may downregulate MAP-2A expression by inhibiting histone deacetylases, leading to hyperacetylation of histone proteins and a subsequent alteration of chromatin accessibility at the MAP-2A gene promoter. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNA methyltransferase inhibitor could decrease MAP-2A expression by inducing hypomethylation of its gene promoter, which may disrupt binding of methyl-CpG-binding proteins and transcriptional repressors, leading to transcriptional silencing. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG 108 may downregulate MAP-2A by inhibiting DNA methyltransferase enzymes, leading to demethylation of CpG islands near the MAP-2A gene promoter, which could interfere with the binding of transcription factors and co-repressors that facilitate gene expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid could decrease the expression of MAP-2A by inhibiting histone deacetylase activity, which may result in a relaxed chromatin state and hinder the recruitment of transcriptional machinery to the MAP-2A gene. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
By incorporating into DNA and inhibiting methyltransferases, 5-Aza-2′-Deoxycytidine can lead to a reduction in DNA methylation levels at the MAP-2A gene locus, potentially disrupting interactions with methyl-CpG-binding domain proteins and repressive transcription complexes. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A can bind to DNA and selectively inhibit transcription of the MAP-2A gene by displacing Sp1 transcription factor from GC-rich recognition sites in the gene's promoter region, leading to reduced transcription initiation. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D could decrease MAP-2A levels by intercalating into DNA and preventing the elongation phase of RNA polymerase during MAP-2A mRNA synthesis, thereby reducing its overall mRNA production. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate may inhibit MAP-2A expression by inhibiting histone deacetylases, which increases acetylation of histones near the MAP-2A promoter, possibly reducing the efficiency of transcription factor binding and gene expression initiation. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram could decrease the expression of MAP-2A by inhibiting the activity of the 26S proteasome, which may lead to the accumulation of ubiquitinated transcription factors that negatively regulate MAP-2A gene transcription. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 can inhibit the proteasome-mediated degradation of inhibitor proteins that bind to and repress the MAP-2A promoter, leading to a decrease in MAP-2A gene transcription. | ||||||